Monday, November 13, 2017 9:23:47 AM
We currently estimate our fourth quarter revenue to range between $7.0 and $7.5 million with Adjusted EBITDA between $3.0 and $3.5 million. Based on our fourth quarter estimate, our full year 2017 revenue is projected to range from $22.3 to $22.8 million compared to $13.3 million in 2016 and our Adjusted EBITDA for 2017 is projected to be range from $8.6 to $9.1 million compared to $1.3 million in 2016.
Recent ZYXI News
- Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award • PR Newswire (US) • 04/02/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:15:17 PM
- Zynex Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 02/29/2024 09:01:00 PM
- Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call • PR Newswire (US) • 02/22/2024 02:15:00 PM
- Zynex Introduces New Products • PR Newswire (US) • 02/20/2024 02:15:00 PM
- Sichenzia Ross Ference Carmel LLP Closes Over 100 Capital Markets Transactions Valued At Over $700 Million in 2023 • GlobeNewswire Inc. • 02/08/2024 02:00:00 PM
- Zynex Receives FDA Clearance for its Next Generation NMES Device • PR Newswire (US) • 02/06/2024 02:15:00 PM
- Zynex Recognized in Top 25 Medical Device Companies for 2024 • PR Newswire (US) • 02/02/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:55:32 PM
- Zynex to Participate at the Needham Annual Growth Conference • PR Newswire (US) • 01/08/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:15:06 PM
- Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024" • PR Newswire (US) • 11/15/2023 02:15:00 PM
- Zynex Submits FDA Application for its Next Generation NMES Device • PR Newswire (US) • 11/13/2023 02:15:00 PM
- Zynex Named as a Winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th Consecutive Year • PR Newswire (US) • 11/09/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 01:20:20 PM
- Zynex Announces Share Repurchase Program • PR Newswire (US) • 11/01/2023 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 10:50:12 AM
- Zynex Announces Review of Strategic Alternatives • PR Newswire (US) • 10/31/2023 10:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 09:01:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:05:38 PM
- Zynex Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 10/26/2023 08:01:00 PM
- Zynex Recognized in Top 100 Healthcare Technologies Companies for Second Year in a Row • PR Newswire (US) • 10/19/2023 01:15:00 PM
UC Asset Expected to Report $0.03/share Net Profit for 2023 • UCASU • Apr 11, 2024 10:00 AM
Kona Gold Beverages & Apple Rush Co. Execute Joint Venture & Manufacturing Agreement • APRU • Apr 11, 2024 9:40 AM
VAYK Confirmed Its Eligibility for $1.8 Million Investment through Federal EB5 Program • VAYK • Apr 11, 2024 9:00 AM
ILUS Moves Forward With Its Two Subsidiary Uplists and Equity Dividend • ILUS • Apr 10, 2024 9:36 AM
Quartz Intersects 102m of 2.22 g/t Au and 104 g/t Ag Announces New Discovery at Prodigy on its Maestro Project, British Columbia • QZM • Apr 10, 2024 8:00 AM
Swifty Global Announces Record Annual Results Ahead of National Exchange Reverse Merger • DRCR • Apr 9, 2024 1:55 PM